The 2024 American College of Rheumatology (ACR ... and rheumatoid arthritis. Data presented by companies like FATE, Cabaletta, and BMS highlighted how CAR-T therapy is reshaping treatment ...

Evidence from observational studies and association guidelines supports the ... and non-escalators (95% CI) In the treatment of rheumatoid arthritis, switching among biologic agents has become ...

I’ve been on 7 - count them - 7 different biologic medicines since being diagnosed with rheumatoid arthritis. I started with several ... 3 One option mentioned in the ACR guidelines is to try multiple ...

Rheumatoid arthritis ... successful treatment of RA is disease heterogeneity, which is also presented in the diverse effects of treatment responses.4 Patients with established RA according to the ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

Understand RA from early to advanced stages. Explore symptoms, treatments, and lifestyle tips to manage rheumatoid arthritis ...

Patients with late-onset rheumatoid arthritis experienced greater functional impairment over 5 years, compared against those with younger-onset disease.

Indian researchers have made a significant leap in the treatment of Rheumatoid Arthritis (RA) with a revolutionary “self-actuating” drug delivery system. This cutting-edge approach aims to ...

Arthritis and bursitis are common joint pain causes, but differ in origin and treatment ... The most common types are osteoarthritis and rheumatoid arthritis. Osteoarthritis typically results ...

Rheumatoid arthritis (RA) is an inflammatory arthritis characterized by chronic joint inflammation, cartilage degradation, and bone erosion.

Women with an age at first birth younger than 26 or older than 35 years have a higher risk for developing rheumatoid arthritis later in life.

Protein disulfide isomerases (PDIs) are essential enzymes that facilitate the proper folding of proteins and maintain protein quality within the endoplasmic reticulum.